Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways

Neurotoxicology. 2019 May:72:74-84. doi: 10.1016/j.neuro.2019.02.004. Epub 2019 Feb 8.

Abstract

Background: Methamphetamine is a neuro-stimulant with neurodegenerative effects, and ambiguous mechanism of action. Metformin is an antidiabetic agent with neuroprotective properties but not fully understood mechanisms. The present study investigated the molecular basis of metformin neuroprotection against methamphetamine-induced neurodegeneration.

Brief method: Sixty adult male rats were randomly divided into six groups: group 1 (received normal saline), group 2 (received 10 mg/kg of methamphetamine) and groups 3, 4, 5 and 6 [received methamphetamine (10 mg/kg) plus metformin (50, 75, 100 and 150 mg/kg) respectively]. Elevated Plus Maze (EPM), Open Field Test (OFT), Forced Swim Test (FST), Tail Suspension Test (TST) and Morris Water Maze (MWM) were used to assess the level of anxiety, depression and cognition in experimental animals. Also animals' hippocampus were isolated and oxidative stress and inflammatory parameters and expression of total and phosphorylated forms of cAMP response element binding (CREB), brain-derived neurotrophic factor (BDNF), protein kinase B (Akt) and glycogen synthase kinase 3 (GSK3) proteins were evaluated by ELISA method.

Results: According to the data obtained, methamphetamine caused significant depression, anxiety, motor activity disturbances and cognition impairment in experimental animals. Metformin, in all used doses, decreased methamphetamine induced behavioral disturbances. Also chronic administration of methamphetamine could increase malondialdehyde (MDA), tumor necrosis factor-Alpha (TNF-α) and interleukine-1 beta (IL-1β) in rats, while caused reduction of superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GR) activities. Metformin, especially in high doses, could prevent these malicious effects of methamphetamine. Also Metformin could activate CREB (both forms), BDNF and Akt (both forms) proteins' expression and inhibited GSK3 (both forms) protein expression in methamphetamine treated rats.

Significance: According to obtained data, metformin could protect the brain against methamphetamine-induced neurodegeneration probably by mediation of CREB/BDNF or Akt/GSK3 signaling pathways. These data suggested that CREB/BDNF or Akt/GSK3 signaling pathways may have a critical role in methamphetamine induced neurotoxicity and/or neuroprotective effects of metformin.

Keywords: Akt/GSK3; Anxiety; CREB/BDNF; Cognition impairment; Depression; Metformin; Methamphetamine.

MeSH terms

  • Animals
  • Anxiety / chemically induced
  • Anxiety / metabolism
  • Anxiety / prevention & control*
  • Brain-Derived Neurotrophic Factor / metabolism
  • Central Nervous System Stimulants / toxicity*
  • Cognitive Dysfunction / chemically induced
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / prevention & control*
  • Cyclic AMP Response Element-Binding Protein / metabolism
  • Depression / chemically induced
  • Depression / metabolism
  • Depression / prevention & control*
  • Glycogen Synthase Kinase 3 / metabolism
  • Hypoglycemic Agents / administration & dosage
  • Male
  • Metformin / administration & dosage*
  • Methamphetamine / toxicity*
  • Neuroprotective Agents / administration & dosage*
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Signal Transduction / drug effects*

Substances

  • Bdnf protein, rat
  • Brain-Derived Neurotrophic Factor
  • Creb1 protein, rat
  • Central Nervous System Stimulants
  • Cyclic AMP Response Element-Binding Protein
  • Hypoglycemic Agents
  • Neuroprotective Agents
  • Methamphetamine
  • Metformin
  • Proto-Oncogene Proteins c-akt
  • Glycogen Synthase Kinase 3